KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Receivables: 2018-2025

Historic Change in Receivables for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to -$1.9 million.

  • Castle Biosciences' Change in Receivables fell 144.92% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165,000, marking a year-over-year decrease of 98.73%. This contributed to the annual value of $12.6 million for FY2024, which is 15.32% down from last year.
  • Castle Biosciences' Change in Receivables amounted to -$1.9 million in Q3 2025, which was up 51.13% from -$3.9 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Change in Receivables peaked at $5.8 million during Q3 2023, and registered a low of -$3.9 million during Q2 2025.
  • Moreover, its 3-year median value for Change in Receivables was $3.6 million (2023), whereas its average is $2.5 million.
  • Per our database at Business Quant, Castle Biosciences' Change in Receivables crashed by 858.33% in 2021 and then spiked by 11,502.00% in 2023.
  • Castle Biosciences' Change in Receivables (Quarterly) stood at -$1.5 million in 2021, then soared by 137.09% to $540,000 in 2022, then skyrocketed by 113.15% to $1.2 million in 2023, then tumbled by 33.19% to $769,000 in 2024, then plummeted by 144.92% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$3.9 million for Q2 2025, and $5.2 million during Q1 2025.